SARS-Cov-2 Specific Antibody Responses in COVID-19 Patients

Epidemiological studies are urgently needed to help uncover the burden of disease, in particular, the rate of asymptomatic infections, and to get better estimates on morbidity and mortality.

An international team of scientists working with the Erasmus Medical Center (Rotterdam, the Netherlands) developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. They used serum samples from patients with polymerase chain reaction (PCR)-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, and they validated and tested various antigens in different in-house and commercial enzyme-linked immunosorbent assays (ELISAs).

The investigators performed Anti-SARS-CoV-2 IgG and IgA ELISAs using beta-versions of two commercial kits (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany). They performed the in-house ELISAs by coating 96-well microtiter ELISA plates with in-house produced spike antigens (S or S1 of SARS-CoV-2, SARS-CoV or MERS-CoV; or SARS-CoV-2 S1A, or RBD proteins) or SARS-N in PBS overnight at 4°C.After processing, the absorbance of each sample was measured at 450 nm.

The scientists demonstrated that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs. They found that commercial S1 IgG or IgA ELISAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity. They compared the performance of the different ELISAs for the detection of antibodies among PCR-confirmed COVID-19 patients to that of plaque reduction neutralization assay (PRNT), as the gold standard for CoV serology. PRNT50 correlated strongly with the different ELISAs, with the commercial IgA showing the strongest correlation followed by the S and N ELISAs indicating their capacity to detect SARS-CoV-2 specific antibodies.

The authors concluded that overall, the validated assays described here can be instrumental for the detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiological and vaccine evaluation studies. The study was published on March 20, 2020 in the pre-publications journal medRxiv.

Related Links:
Erasmus Medical Center
EUROIMMUN